CA2577543A1 - Variants d'anticorps et fragments de ceux-ci - Google Patents

Variants d'anticorps et fragments de ceux-ci Download PDF

Info

Publication number
CA2577543A1
CA2577543A1 CA002577543A CA2577543A CA2577543A1 CA 2577543 A1 CA2577543 A1 CA 2577543A1 CA 002577543 A CA002577543 A CA 002577543A CA 2577543 A CA2577543 A CA 2577543A CA 2577543 A1 CA2577543 A1 CA 2577543A1
Authority
CA
Canada
Prior art keywords
variant
amino acid
region
igg
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002577543A
Other languages
English (en)
Other versions
CA2577543C (fr
Inventor
Esohe Ekinaduese Idusogie
Michael George Mulkerrin
Leonard G. Presta
Robert Laird Shields
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Esohe Ekinaduese Idusogie
Michael George Mulkerrin
Leonard G. Presta
Robert Laird Shields
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/054,255 external-priority patent/US6242195B1/en
Application filed by Genentech, Inc., Esohe Ekinaduese Idusogie, Michael George Mulkerrin, Leonard G. Presta, Robert Laird Shields filed Critical Genentech, Inc.
Priority claimed from CA2323757A external-priority patent/CA2323757C/fr
Publication of CA2577543A1 publication Critical patent/CA2577543A1/fr
Application granted granted Critical
Publication of CA2577543C publication Critical patent/CA2577543C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2577543A 1998-04-02 1999-03-31 Variants d'anticorps et fragments de ceux-ci Expired - Lifetime CA2577543C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/054,255 US6242195B1 (en) 1998-04-02 1998-04-02 Methods for determining binding of an analyte to a receptor
US09/054,255 1998-04-02
US11610099P 1999-01-15 1999-01-15
US60/116,100 1999-01-15
CA2323757A CA2323757C (fr) 1998-04-02 1999-03-31 Variants d'anticorps et fragments de ceux-ci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2323757A Division CA2323757C (fr) 1998-04-02 1999-03-31 Variants d'anticorps et fragments de ceux-ci

Publications (2)

Publication Number Publication Date
CA2577543A1 true CA2577543A1 (fr) 1999-10-14
CA2577543C CA2577543C (fr) 2016-05-31

Family

ID=37912395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2577543A Expired - Lifetime CA2577543C (fr) 1998-04-02 1999-03-31 Variants d'anticorps et fragments de ceux-ci

Country Status (1)

Country Link
CA (1) CA2577543C (fr)

Also Published As

Publication number Publication date
CA2577543C (fr) 2016-05-31

Similar Documents

Publication Publication Date Title
EP3176181B1 (fr) Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l'antigène, composition médicinale et son utilisation
CA2067031C (fr) Adn codant pour l'antigene de surface de cellules humaines
KR100917262B1 (ko) 재조합 항-cd40 항체 및 그의 용도
JP6694712B2 (ja) Cd269(bcma)に対する抗体
WO2018028635A1 (fr) Anticorps monoclonal humanisé contre le virus zika et ses applications
JP3276369B2 (ja) 改良ヒト化免疫グロブリン
CN102428103B (zh) 抗light的人源化抗体及其使用
CA2623458A1 (fr) Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins
KR20010099807A (ko) 감마 인터페론에 대한 인간화 항체
CA2123894A1 (fr) Anticorps heterodimeriques bispecifiques
JPH08507201A (ja) リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
CA2674838A1 (fr) Vaccins anti-ige
EP3896085A1 (fr) Anticorps monoclonal anti-interleukine 5(il-5) humaine et son utilisation
KR20080045765A (ko) 인터페론 알파 수용체-1에 대한 인체화 항체
EP4063385A1 (fr) Anticorps gipr et protéine de fusion entre celui-ci et la glp-1, et composition pharmaceutique et application associée
TWI701260B (zh) 抗pacap抗體
KR20140135766A (ko) 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법
EP2365983A1 (fr) Peptides dérivés d il-4 pour la modulation de la réponse inflammatoire chronique et le traitement de maladies auto-immunes
EP3808771A1 (fr) Anticorps gipr et proteine de fusion glp-1 de ce dernier, et composition pharmaceutique et son application
JP2023542049A (ja) インターロイキン-2ムテイン及びその使用
CN112159473B (zh) 重组人源化抗人白介素23单克隆抗体的纯化方法
KR102498976B1 (ko) pH-감응성 Fc 변이체
CA2577543A1 (fr) Variants d'anticorps et fragments de ceux-ci
CN113354737B (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
IL108776A (en) A method of dissolving a cell or inhibiting cell growth, a bispecific molecule that binds FNT-1R and an SAF antibody, a medical preparation that contains it and its use

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190401